Respiratory Syncytial Virus Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - Daiichi Sankyo Company, Enanta Pharmaceuticals, Modern

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Respiratory Syncytial Virus pipeline constitutes 50+ key companies continuously working towards developing 50+ Respiratory Syncytial Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Respiratory Syncytial Virus Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Respiratory Syncytial Virus Market.

The Respiratory Syncytial Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Respiratory Syncytial Virus Pipeline Report: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Respiratory Syncytial Virus treatment therapies with a considerable amount of success over the years.
• Respiratory Syncytial Virus companies working in the treatment market are Daiichi Sankyo Company, Enanta Pharmaceuticals, Moderna, Inc., Bavarian Nordic, Johnson & Johnson, Ark Biosciences, Calder Biosciences Inc., ICOSAVAX, INC, Codagenix, Inc., Meissa Vaccines, Inc., and others, are developing therapies for the Respiratory Syncytial Virus treatment
• Emerging Respiratory Syncytial Virus therapies such as - VN-0200, EDP-938, mRNA-1345, MVA-BN RSV, VAC18193, AK0611, DT-PreF, IVX-121, CodaVax-RSV, MV-012-968, and others are expected to have a significant impact on the Respiratory Syncytial Virus market in the coming years.
• In May 2023, Arexvy, a vaccine against the respiratory syncytial virus (RSV), was approved by the US Food and Drug Administration, according to GSK, making it the first vaccination of its sort ever created.
• In April 2022, In order to assess the efficacy, safety, reactogenicity, and immunogenicity of an Ad26.RSV.preF-based vaccine in Japanese adults aged 60 years and older, as well as the safety, reactogenicity, and immunogenicity of the vaccine in Japanese adults aged 20 to 59 years at high risk of RSV disease, Johnson & Johnson initiated a Phase III, a randomised, double-blind, placebo-controlled phase 3 study
• In November 2022, To assess the effectiveness and safety of edp-938 in non-hospitalized persons with acute respiratory syncytial virus infection who are at high risk for consequences, Enanta started a Phase 2IIb, randomised, double-blind, placebo-controlled research. The experiment is presently accepting volunteers and is anticipated to have 180 by April 2024
• In July 2021, A randomised, double-blind, placebo-controlled Phase III effectiveness study of an Ad26.RSV.preF-based vaccination for the prevention of lower respiratory tract disease brought on by RSV in adults 60 years of age and older was started by Johnson & Johnson
• In January 2020, Enanta started a multicenter, randomised, double-blind, placebo-controlled Phase II research to examine the effectiveness, safety, and tolerability of EDP-938 given orally to people with RSV infection. Subjects (18 to 75 years old, inclusive) who have had upper respiratory symptoms for up to 48 hours and who have tested positive for respiratory syncytial virus (RSV) but negative for influenza virus

Get a Free Sample PDF Report to know more about Respiratory Syncytial Virus Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Respiratory Syncytial Virus Drugs Under Different Phases of Clinical Development Include:
• VN-0200: Daiichi Sankyo Company
• EDP-938: Enanta Pharmaceuticals
• mRNA-1345: Moderna, Inc.
• MVA-BN RSV: Bavarian Nordic
• VAC18193: Johnson & Johnson
• AK0611: Ark Biosciences
• DT-PreF: Calder Biosciences Inc.
• IVX-121: ICOSAVAX, INC
• CodaVax-RSV: Codagenix, Inc
• MV-012-968: Meissa Vaccines, Inc.

Route of Administration
Respiratory Syncytial Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Respiratory Syncytial Virus Pipeline Therapeutics Assessment
• Respiratory Syncytial Virus Assessment by Product Type
• Respiratory Syncytial Virus By Stage and Product Type
• Respiratory Syncytial Virus Assessment by Route of Administration
• Respiratory Syncytial Virus By Stage and Route of Administration
• Respiratory Syncytial Virus Assessment by Molecule Type
• Respiratory Syncytial Virus by Stage and Molecule Type

DelveInsight's Respiratory Syncytial Virus Report covers around 50+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Respiratory Syncytial Virus product details are provided in the report. Download the Respiratory Syncytial Virus pipeline report to learn more about the emerging Respiratory Syncytial Virus therapies at:
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Respiratory Syncytial Virus Therapeutics Market include:
Key companies developing therapies for Respiratory Syncytial Virus are - GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.

Respiratory Syncytial Virus Pipeline Analysis:
The Respiratory Syncytial Virus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Respiratory Syncytial Virus with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus Treatment.
• Respiratory Syncytial Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Respiratory Syncytial Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Respiratory Syncytial Virus drugs and therapies- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Respiratory Syncytial Virus Pipeline Market Drivers
• Rising government funding for treatment and proactive government initiatives generates profitable opportunities, the growing disease rate, advent of Targeted Therapies are some of the important factors that are fueling the Respiratory Syncytial Virus Market.

Respiratory Syncytial Virus Pipeline Market Barriers
• However, lack of adequate diagnostic facilities for RSV, limited awareness among parents and other factors are creating obstacles in the Respiratory Syncytial Virus Market growth.

Scope of Respiratory Syncytial Virus Pipeline Drug Insight
• Coverage: Global
• Key Respiratory Syncytial Virus Companies: , and others
• Key Respiratory Syncytial Virus Therapies: VN-0200, EDP-938, mRNA-1345, MVA-BN RSV, VAC18193, AK0611, DT-PreF, IVX-121, CodaVax-RSV, MV-012-968, and others
• Respiratory Syncytial Virus Therapeutic Assessment: Respiratory Syncytial Virus current marketed and Respiratory Syncytial Virus emerging therapies
• Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and Respiratory Syncytial Virus market barriers

Request for Sample PDF Report for Respiratory Syncytial Virus Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Respiratory Syncytial Virus Report Introduction
2 Respiratory Syncytial Virus Executive Summary
3 Respiratory Syncytial Virus Overview
4 Respiratory Syncytial Virus- Analytical Perspective In-depth Commercial Assessment
5 Respiratory Syncytial Virus Pipeline Therapeutics
6 Respiratory Syncytial Virus Late Stage Products (Phase II/III)
7 Respiratory Syncytial Virus Mid Stage Products (Phase II)
8 Respiratory Syncytial Virus Early Stage Products (Phase I)
9 Respiratory Syncytial Virus Preclinical Stage Products
10 Respiratory Syncytial Virus Therapeutics Assessment
11 Respiratory Syncytial Virus Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Respiratory Syncytial Virus Key Companies
14 Respiratory Syncytial Virus Key Products
15 Respiratory Syncytial Virus Unmet Needs
16 Respiratory Syncytial Virus Market Drivers and Barriers
17 Respiratory Syncytial Virus Future Perspectives and Conclusion
18 Respiratory Syncytial Virus Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Respiratory Syncytial Virus Market https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Respiratory Syncytial Virus-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Respiratory Syncytial Virus Epidemiology https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Respiratory Syncytial Virus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.